

M Javad Aman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/946341/publications.pdf>

Version: 2024-02-01

45
papers

2,828
citations

186265
28
h-index

233421
45
g-index

45
all docs

45
docs citations

45
times ranked

3303
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipid Raft Microdomains. <i>Journal of Experimental Medicine</i> , 2002, 195, 593-602.	8.5	419
2	Ebola Virus-“Like Particle”-Based Vaccine Protects Nonhuman Primates against Lethal Ebola Virus Challenge. <i>Journal of Infectious Diseases</i> , 2007, 196, S430-S437.	4.0	236
3	Ebola virus-like particles protect from lethal Ebola virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15889-15894.	7.1	231
4	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. <i>Cell</i> , 2018, 174, 938-952.e13.	28.9	173
5	Lower Antibody Levels to Staphylococcus aureus Exotoxins Are Associated With Sepsis in Hospitalized Adults With Invasive S. aureus Infections. <i>Journal of Infectious Diseases</i> , 2012, 206, 915-923.	4.0	122
6	Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. <i>Vaccine</i> , 2005, 23, 3033-3042.	3.8	119
7	Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. <i>FEMS Immunology and Medical Microbiology</i> , 2004, 40, 27-31.	2.7	113
8	Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. <i>Cell</i> , 2017, 169, 891-904.e15.	28.9	103
9	A “Trojan horse”-bispecific-antibody strategy for broad protection against ebolaviruses. <i>Science</i> , 2016, 354, 350-354.	12.6	101
10	Novel Structurally Designed Vaccine for S. aureus α -Hemolysin: Protection against Bacteremia and Pneumonia. <i>PLoS ONE</i> , 2012, 7, e38567.	2.5	83
11	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. <i>Cell Reports</i> , 2016, 15, 1514-1526.	6.4	80
12	Filovirus-“Like Particles Produced in Insect Cells: Immunogenicity and Protection in Rodents. <i>Journal of Infectious Diseases</i> , 2007, 196, S421-S429.	4.0	79
13	Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. <i>Journal of Virology</i> , 2016, 90, 279-291.	3.4	72
14	Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. <i>Cell Reports</i> , 2017, 19, 413-424.	6.4	66
15	Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction. <i>Frontiers in Microbiology</i> , 2016, 7, 1765.	3.5	62
16	Advances in Virus-Like Particle Vaccines for Filoviruses. <i>Journal of Infectious Diseases</i> , 2011, 204, S1053-S1059.	4.0	51
17	Monoclonal antibody therapy for Junin virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4458-4463.	7.1	50
18	Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles. <i>PLoS ONE</i> , 2015, 10, e0118881.	2.5	50

#	ARTICLE	IF	CITATIONS
19	<i>NCKAP1L</i> defects lead to a novel syndrome combining immunodeficiency, lymphoproliferation, and hyperinflammation. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	48
20	Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates. <i>Nature Communications</i> , 2019, 10, 105.	12.8	45
21	Analysis of Ebola virus and VLP release using an immunocapture assay. <i>Journal of Virological Methods</i> , 2005, 127, 1-9.	2.1	43
22	Structurally Designed Attenuated Subunit Vaccines for <i>S. aureus</i> LukS-PV and LukF-PV Confer Protection in a Mouse Bacteremia Model. <i>PLoS ONE</i> , 2013, 8, e65384.	2.5	43
23	Protective efficacy of a novel alpha hemolysin subunit vaccine (AT62) against <i>Staphylococcus aureus</i> skin and soft tissue infections. <i>Vaccine</i> , 2016, 34, 6402-6407.	3.8	41
24	Involvement of Vacuolar Protein Sorting Pathway in Ebola Virus Release Independent of TSG101 Interaction. <i>Journal of Infectious Diseases</i> , 2007, 196, S264-S270.	4.0	40
25	Ebola Virus VP40 Modulates Cell Cycle and Biogenesis of Extracellular Vesicles. <i>Journal of Infectious Diseases</i> , 2018, 218, S365-S387.	4.0	40
26	Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax. <i>Vaccine Journal</i> , 2016, 23, 918-925.	3.1	38
27	The Role of Exosomal VP40 in Ebola Virus Disease. <i>DNA and Cell Biology</i> , 2017, 36, 243-248.	1.9	35
28	Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins. <i>PLoS Pathogens</i> , 2019, 15, e1008061.	4.7	35
29	Extracellular Vesicles and Ebola Virus: A New Mechanism of Immune Evasion. <i>Viruses</i> , 2019, 11, 410.	3.3	27
30	Antibodies to <i>S. aureus</i> LukS-PV Attenuated Subunit Vaccine Neutralize a Broad Spectrum of Canonical and Non-Canonical Bicomponent Leukotoxin Pairs. <i>PLoS ONE</i> , 2015, 10, e0137874.	2.5	26
31	Structural basis for broad neutralization of ebolaviruses by an antibody targeting the glycoprotein fusion loop. <i>Nature Communications</i> , 2018, 9, 3934.	12.8	25
32	Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. <i>Journal of Infectious Diseases</i> , 2018, 218, S553-S564.	4.0	22
33	IBT-V02: A Multicomponent Toxoid Vaccine Protects Against Primary and Secondary Skin Infections Caused by <i>Staphylococcus aureus</i> . <i>Frontiers in Immunology</i> , 2021, 12, 624310.	4.8	17
34	TBA225, a fusion toxoid vaccine for protection and broad neutralization of staphylococcal superantigens. <i>Scientific Reports</i> , 2019, 9, 3279.	3.3	12
35	Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	12
36	Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans. <i>Antiviral Research</i> , 2016, 126, 55-61.	4.1	11

#	ARTICLE	IF	CITATIONS
37	Chasing Ebola through the Endosomal Labyrinth. MBio, 2016, 7, e00346.	4.1	10
38	Atypical Ebola Virus Disease in a Nonhuman Primate following Monoclonal Antibody Treatment Is Associated with Glycoprotein Mutations within the Fusion Loop. MBio, 2021, 12, .	4.1	10
39	Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	8
40	Reduced-Beclin1-Expressing Mice Infected with Zika-R103451 and Viral-Associated Pathology during Pregnancy. Viruses, 2020, 12, 608.	3.3	7
41	Integrated BioTherapeutics. Human Vaccines and Immunotherapeutics, 2018, 14, 1308-1310.	3.3	6
42	Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. Journal of Virology, 2021, 95, .	3.4	6
43	The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection. IScience, 2021, 24, 102266.	4.1	6
44	Safety and Immunogenicity of a 4-Component Toxoid-Based Staphylococcus aureus Vaccine in Rhesus Macaques. Frontiers in Immunology, 2021, 12, 621754.	4.8	4
45	Hyperimmune Targeting Staphylococcal Toxins Effectively Protect Against USA 300 MRSA Infection in Mouse Bacteremia and Pneumonia Models. Frontiers in Immunology, 2022, 13, .	4.8	1